Home › Trial NCT00349349
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
- Trial IDNCT00349349
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorGlaxoSmithKline
- Enrollment223
- Start date2006-06
- ConditionsLeukaemia, Lymphocytic, Chronic
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.